Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27812796 | 0.82 | NAMPT (0.55) | ATMNAMPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL5421718 | 0.80 | HSD11B1 (0.78) | HSD11B1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1856848 | 0.80 | HSD11B1 (0.71) | HSD11B1SMN1; SMN2POLBNOTUMSMO | |
| SCHEMBL1856847 | 0.80 | HSD11B1 (0.71) | HSD11B1SMN1; SMN2POLBNOTUMSMO | |
| SCHEMBL1857680 | 0.79 | HSD11B1 (0.67) | HSD11B1SMN1; SMN2POLBSMO | |
| SCHEMBL1857858 | 0.78 | HSD11B1 (0.66) | HSD11B1SMN1; SMN2POLBSMO | |
| SCHEMBL1860172 | 0.78 | HSD11B1 (0.62) | HSD11B1SMN1; SMN2POLBSMOTSHR | |
| SCHEMBL1854997 | 0.76 | HSD11B1 (0.79) | HSD11B1SMN1; SMN2POLBNOTUMSMO | |
| SCHEMBL1860343 | 0.76 | HSD11B1 (0.68) | HSD11B1SMN1; SMN2POLBNOTUMSMO | |
| SCHEMBL1856555 | 0.76 | HSD11B1 (0.67) | HSD11B1SMN1; SMN2POLBNOTUMSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885ATM 4604/4885SMN1; SMN2 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.